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ABSTRACT 
 
Tuberculosis (TB) remains a leading cause of death despite the availability of drug 
treatments.  Antibiotic resistance resulting from human behavior and genetic mutation has led to 
the development of both multi drug-resistant and extensively drug-resistant tuberculosis, further 
complicating successful intervention.  Antimicrobial peptides (AMPs) present a novel alternative 
to standard antibiotic therapies.  In this study, we used flow cytometry to measure the 
cytotoxicity of three different synthetic AMPs (A4S7, D8 and WLBU2) on human monocyte-
like cell lines and macaque macrophages.  Both WLBU2 and A4S7 were associated with 
significant cell death (p < 0.05) at, and above, concentrations of 10 μM, and the results for D8 
varied by cell type.  The data obtained in this study will inform future experiments on bacteria 
and co-infected cells, from which the plausibility of specific AMPs as treatments for 
Mycobacterium tuberculosis can be assessed and provide insights of clear public health 
significance. 
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PREFACE 
I would like to extend my sincerest thanks to Dr. Mattila and Dr. Deslouches for their guidance 
and support throughout the process of writing this essay.  I would also like to thank the members 
of Dr. Mattila’s lab, Beth Junecko and Dr. Jia Yao Phuah, for their instruction and unwavering 
patience. There is little doubt that my success is due, in no small part, to their collective 
contributions, and I would invite them to share in the satisfaction that comes from this 
achievement.   
This assembly of experiments, while introductory in complexity to the seasoned 
immunologist, is the result of countless hours of laboratory training that I was fortunate to 
receive from some of the most highly skilled individuals.  It is humbling to admit that you know 
very little, but not nearly as humbling as the moment when you realize how little you actually 
knew.  There are few moments more personally insightful and professionally rewarding, and I 
would like to thank everyone who contributed to that end. 
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1.0  INTRODUCTION 
Tuberculosis (TB), an infection caused by Mycobacterium tuberculosis, is the ninth leading 
cause of death worldwide [1]. Compared to both the leading and second leading causes of death 
(ischaemic heart disease and stroke, respectively), communicable diseases like tuberculosis 
cannot simply be prevented through behavioral or lifestyle changes [1].  The total number of 
individuals killed by this pathogen, to date, is estimated to be over 1 billion, with an additional 
1.37 million deaths occurring in 2016 [1].  Following genetic analysis of tissue samples, 
exhumed Egyptian mummies from 2050 BCE were found to have M. tuberculosis DNA; a 
sobering fact that speaks to both the historic resilience of this unique microorganism and an 
intergenerational human dilemma [2].  The World Health Organization (WHO) reports that $6.9 
billion was allocated in 2017 for addressing global tuberculosis prevention, case identification, 
and treatment, which is $2.3 billion less than the total amount the WHO estimated to be 
necessary for a comprehensive response [3].  This figure discounts an additional $9 billion in 
research and development estimated to be necessary for just 2017 [3].   Financially, deaths 
resulting from tuberculosis impact GDP to an even greater extent.  In 2014 there were $50.4 
billion in estimated GDP losses (excluding health spending) attributed to 753,000 TB deaths 
occurring only within the WHO-defined African Region [4].  Infected individuals that are too ill 
to work, isolated to prevent transmission of TB, or both, are unaccounted for in these financial 
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models, suggesting that estimates of the economic impact of TB significantly underrepresent the 
true economic impact of TB in this region 
While the global financial consequences of tuberculosis infections are staggering, the 
burden of new infections is disproportionately disseminated around the world.  As of 2016, 87% 
of the 10.4 million new TB cases arose in WHO-defined South-East Asia, Africa, and Pacific 
regions [3].  The majority of new TB infections were identified in India with 2.79 million 
identified cases, which translates to 109-345 new infections per 100,000 people [3].  In response 
to the continued epidemic, the WHO proposed the “End TB Strategy” that aims to reduce new 
TB cases by 90% and TB-derived deaths by 95% between 2015 and 2035, with a 50% reduction 
in incidence and a 75% reduction in mortality benchmark by 2025 [5].  A feasibility study was 
conducted in 2016 that employed 11 different mathematical models to try and determine if the 
2025 benchmark was plausible in high-burden countries, where the need for success is greatest.  
The authors concluded that while significant reductions in infectious burden were possible with 
current approaches, the cumulative consequence of massive increases in all individual 
interventions would still be insufficient to reach WHO goals in high-burden countries like India 
and China [6].  In short, the evidence suggests that the global community is presently under-
funding a strategy for combating an epidemic that, when adequately funded, would still fail to 
meet its own goals in countries most affected. 
 M. tuberculosis, the primary causative agent of TB cases in humans, sits 
phylogenetically alongside M. leprae (the causative agent of leprosy) in the Mycobacterium 
genus [7].  The small (1-5 microns in diameter), curved bacillus is a non-motile obligate aerobe.  
Human lungs provide an optimal environment for M. tuberculosis as a consistent source of 
oxygen and a means for dissemination to new intra-host sites and transmission to new hosts [8].  
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Mycobacteria can survive in dry environments for up to five months without succumbing to 
desiccation, in no small part because of their unique waxy layer of mycolic acids from which 
their name derives [7, 8, 9].  This feature is highly immunogenic and promotes intra-host 
survival but also likely contributes to host evasion as the bacteria can lie dormant in an infected 
host for decades.  
Despite the ability of mycobacteria to persist on dry surfaces, M. tuberculosis is not 
transmitted from contact with infected surfaces [8].  Coughing, singing, or even speaking can 
spread the bacteria through droplet transmission, but physical contact like kissing has not been 
shown to result in transmission [7, 8].  Additionally, the probability of transmission is affected 
by the duration of interactions between infected and uninfected individuals and ventilation in 
confined spaces [8].  Friends and family members of infected individuals are encouraged to 
employ social distancing to avoid infection, even in developed countries where incidence rates 
are near zero [10].  However, self-segregation is a predictably unreasonable request for infected 
individuals in developing countries where resources are scarce, and the healthcare infrastructure 
is unstable.   
 A defining feature of M. tuberculosis is the unique intracellular approach by which it 
evades host defenses. As the lungs are the initial site of M. tuberculosis infection, upon 
inhalation, alveolar macrophages engulf the bacteria as part of the innate immune response [7, 8, 
11].  Typically, bacteria-containing phagosomes combine with lysosomes leading to the contents 
being degraded, but M. tuberculosis can prevent phago-lysosomal fusion [7, 11].  Having been 
internalized by the macrophage but not degraded, the bacteria can evade the adaptive immune 
response by preventing presentation of MHC II-bound peptide fragments to CD4+ T cells [7].  As 
a result of the phagosome’s sustained integrity, the macrophage continues to release TNF-α, 
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consistently drawing the attention of additional immune cells.  One suggested consequence of 
this state of chronic inflammation is the formation of a granuloma: a massive ring of 
macrophages and T-cells that encase the infected macrophages [7, 11].  The whole process is 
reminiscent of a medieval army who, having failed to penetrate the city they intended to sack, 
would surround the entire town, and wait for the denizens to starve.  Deprived of nutrients and 
oxygen, the bacteria are either rendered inert or enter a state of non-replication from which they 
may emerge decades later [12].  The mechanism by which the bacteria maintain their integrity is 
not well understood, but some evidence suggests that they may enter a form of sporulation, as 
was demonstrated to occur in Mycobacterium marinum [13].  Latent TB Infection [LTBI] is such 
a common outcome from exposure to TB that it is estimated that at least a quarter of the world’s 
population is infected but shows no clinical signs [3].  TB is presently defined bimodally as 
active vs. latent, but recent evidence from advanced imaging techniques and more extensive 
cultures of patient samples suggest a redefinition.  In the new approach, latency is presented as a 
spectrum of symptoms, with more severe symptoms indicative of infection [14].  
Despite the damage that tuberculosis has wrought, the continued presence of this 
infectious pathogen has been associated with numerous breakthroughs that paved the foundation 
for microbiology.  Koch’s postulates on infectious etiology were first demonstrated with Mtb 
bacillus, and the questionable results of isolation via sanitarium would, at least, provide the 
institutional mindset for antiseptic environments during recovery [15].  In 1921, the BCG 
(Bacille Calmette-Guerin) vaccine was introduced to prevent acquisition, and by the 1950’s there 
were various successful chemotherapy options of promising success for individuals with latent 
and active infections [15, 16]. 
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Both a vaccine and a drug regimen exist, so why are so many people still dying?  After 
80 years of use, data shows that the BCG vaccine has limited efficacy preventing primary 
infection and is presently only recommended by the WHO to HIV-negative newborns to prevent 
extrapulmonary infections [15].  The present course of therapy for an individual with drug-
susceptible TB is a lengthy 6-month course of antimycobacterial drugs, beginning with a 2-
month course of rifampin, isoniazid, pyrazinamide, and ethambutol, and then a 4-month course 
of only rifampin and isoniazid [16].  There are numerous drug combinations and schedules that 
vary depending on drug-susceptibility, age, pregnancy status, location of TB infection, 
concomitant immune disorders (HIV), and organ impairments (renal / hepatic) [16].  Adherence 
to the full course of drugs is a major complication to treatment because of cost, availability of 
drugs, discontinuation upon alleviation of symptoms and serious adverse events.  Some 
administration studies have shown rates of complete adherence to the full drug regimen as low as 
51% [17].  The lack of adherence not only contributes to future infections, but also contributes to 
the development of drug-resistant M. tuberculosis status.  Multidrug-resistant TB [MDR TB] and 
extensively drug-resistant TB [XDR TB] strains have emerged, and the recommended treatment 
schedules are predictably more demanding than the drug-susceptible strains.  Some studies show 
efficacy with a 7-drug combination for 9 months, while others recommend less drugs for a longer 
(20-month minimum) duration [16].  The intensity and duration of the regimen(s), the severity of 
the side effects and the continued loss of life are clear signals that more effective interventions 
are desperately needed. 
In the absence of pharmaceutical interest in the development of new antibiotics, a novel 
strategy for combatting infectious agents has emerged through the use of natural and synthetic 
peptides with antimicrobial properties, or antimicrobial peptides (AMPs).  AMPs are a diverse 
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collection of defensive compounds that exist as part of the innate immune response [18]. 
Compared to traditional antibiotics that aim to disrupt precise mechanisms, AMPs are broadly 
effective as they (in the case of antibacterial peptides) target cell membranes with membrane 
potentials outside the typical array for eukaryotic cells [19].  Through mutations, countless 
conformational changes can be made to a cellular component to avoid disruption, but electrical 
charge is fundamental and viable mutations are less common.  By taking advantage of this 
disparity, AMPs have a unique position of working as a targeted anti-infective and combating the 
notion that resistance to any therapy is practically inevitable [18]. 
In this study, we aimed to acquire pilot data on the interactions between three synthetic 
AMPs (A4S7, D8, and WLBU2) and human monocyte-like cell lines and macaque macrophages 
to identify concentrations at which minimal cytotoxicity is observed.  Although AMPs are 
generally targeted at prokaryotic cells, they can have off-target effects that limit their usefulness.  
WLBU2 has been demonstrated to effectively target P aeruginosa and S aureus in experimental 
models [20]. The data obtained from this study will inform future experiments in bacterial 
models (BCG and Mtb) to identify a minimum inhibitory concentration.  This project has a clear 
public health significance as it aims to provide the foundation for a proof-of-concept on the 
utility of AMPs as a novel treatment for TB, a disease that claims the lives of millions of people 
each year. 
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2.0  MATERIALS AND METHODS 
2.1 DATA ANALYSIS 
Flow cytometry data was analyzed using FlowJo v10 (BD Biosciences, San Jose, CA).  Figures 
and statistics were generated using GraphPad Prism version 7.00 for Windows (GraphPad 
Software, La Jolla CA). 
2.2 TOXICITY ASSAY USING U937 CELLS: TRIALS 1 – 2 
To justify a possible intervention with AMPs in the treatment of Mtb infection, the first question 
that was addressed experimentally was the plausibility of administration to human-like 
monocytes.  An aliquot of human histiocytic lymphoma U937 cells was thawed and introduced 
into R10 Media (88% RPMI Culture Media with 1% L-Glutamine, 10% Fetal Bovine Serum, 1% 
HEPES).  To identify the logarithmic growth phase, cell density and media discoloration were 
observed visually for up to four days, and verification of the presumed growth phase was 
supported with Trypan Blue Exclusion Staining to obtain cell counts.  Once the log phase had 
been confirmed, a subculture was transferred to fresh R10 media and incubated again for four 
days.  No experiments were performed on the first passages to minimize cellular irregularities 
due to cryopreservation. 
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In the absence of preliminary data, a wide range of peptide concentrations were used to 
determine which concentration led to the largest amount of cytotoxicity.  Five concentrations of 
peptide (100 μM, 80 μM, 40 μM, 20 μM and 1 μM) were individually added to U937 cells for a 
total volume of 250 μL per sample.  This was done for each of the three experimental peptides 
(A4S7, D8, WLBU2), totaling 15 conditional samples.  Additionally, two 250 μL controls were 
generated with 10 μL of PBS substituting for the deliberately absent peptides.  The samples were 
incubated for 24 hours.  After 24 hours, the samples were centrifuged at 1800 rpm for 5 minutes 
to form a pellet, the supernatant decanted and the pellet resuspended in a 100 μL mixture of PBS 
and nucleic acid stains (SYTOX Orange and STYO9) in a 1:3000 dilution.  The staining 
procedure was performed in the dark for 15 minutes.  After 15 minutes, the samples were washed 
with 100 μL of PBS, spun at 1800 rpm for 5 minutes and the supernatant was decanted.  The 
washing process was completed three times in total.  One of the two control samples was not 
stained but was washed, consistent with the other samples.  Following the removal of excess 
stain, the samples were fixed in 2% paraformaldeyhde so they could be analyzed by flow 
cytometry.  SYTOX Orange positive cells were presumed dead (% dead cells), and the data 
obtained can be found in Figure 1. 
 Following the completion of Trial 1, the experiment was repeated for reliability (Trial 2).  
All study procedures implemented for Trial 1 were kept consistent except for a fresh U937 
subculture.  Trial 2 data obtained following flow cytometry was averaged with Trial 1 data and 
displayed in Figure 2. 
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2.3 TOXICITY ASSAY USING U937 CELLS: TRIALS 3 – 4 
The data obtained in Trials 1 and 2 suggested that the optimal peptide concentration for minimal 
monocyte death might exist near the two lowest concentrations previously examined: 20 μM and 
1 μM.  A 5-fold dilution series was implemented for the new peptide concentrations, extending 
slightly beyond the previously examined range: 40 μM, 8 μM, 1.6 μM, 0.32 μM, 0.064 μM, 
0.0122 μM.  The experiment was separated into two trials (3 and 4) to increase reliability and 
they were carried out concurrently.  The protocol for Trials 1 and 2 was repeated for Trials 3 and 
4 with few deviations: new peptide concentrations (previously listed), fresh U937 cells, and the 
use of 96-well plates which required less total volume per sample (200 μL).  The “% dead cells” 
obtained from Trials 3 and 4 was averaged and is displayed in Figure 3. 
2.4 TOXICITY ASSAY USING U937 CELLS: TRIALS  5 – 7 
U937 Trials 3 and 4 showed that the optimal peptide concentration was likely not less than 1 μM, 
and Trials 1 and 2 showed that it likely did not exceed 20 μM.  Trial 5 introduced a 2-fold 
dilution series that peaked at 40 μM and extended just slightly below 1 μM with the following 
concentrations: 40 μM, 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM and 0.65 μM.  Trial 5 was 
performed in triplicate (Trials 6 and 7), and the protocol was identical to Trials 3 and 4 except 
for the new peptide concentrations.  The SYTOX Orange positive cell (% dead cells) data 
obtained using flow cytometry was averaged between the three trials and displayed in Figure 4 
and data from statistical analyses are displayed in Table 1. 
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2.5 TOXICITY ASSAY USING THP-1 CELLS: TRIALS 1 – 3 
The culture method employed for THP-1 cells was identical to the culture method for U937 cells.  
The only exception was duration, as THP-1 cells often reach the log phase one day sooner than 
U937 cells. A staining optimization protocol was developed to ensure that the SYTOX Orange 
and SYTO9 stains were taken up by the THP-1 cells to a desirable degree.  Untreated THP-1 
cells were exposed to one of five concentrations of either SYTOX Orange or STYO9 nucleic 
acid stains for 15 minutes.  The cells were washed three times, fixed in 2% PFA and underwent 
flow cytometry. SYTOX Orange at a 1:2000 dilution and STYO9 at a 1:4000 dilution resulted in 
an emission signal within the preferred log range (103 – 105).  The staining portion of the AMP 
assay for the U937 cells was amended with these dilutions for THP-1 cells. 
The antimicrobial peptide protocol for the U937 Trials 5 and 6 was replicated with the 
same peptide concentrations (40 μM, 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM and 0.65 μM), but 
with THP-1 cells instead of U937 cells.  The THP-1 version of the AMP assay was done in 
triplicate on a 96-well plate.  SYTOX Orange positive cell (% dead cells) data obtained from 
flow cytometry for THP Trials 1 – 3 is displayed in Figure 5 and data from statistical analyses 
are displayed in Table 2. 
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2.6 TOXICITY ASSAY USING A549 CELLS:  TRIALS 1 – 2 
A549 cells are an adherent cell line unlike the THP-1 and U937 cells, so a modified AMP assay 
was required.  The A549 cells were cultured in a 96-well tissue culture treated plate and 
incubated for one day so the cells could adhere and grow.  After one day, the cells were exposed 
to one of the three antimicrobial peptides at a concentration consistent with previous 
experiments: 40 μM, 20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μM or 0.65 μM.  The cells were then 
incubated for an additional day with the added peptides.  Two wells of A549 cells were not 
exposed to any peptides (only PBS) throughout the experiment to function as controls.  On the 
third day, the media was discarded, the cells were washed and then stained with SYTOX Orange 
(1:2000) and SYTO9 (1:4000) for 15 minutes.  The stain dilutions had been determined during 
an optimization protocol that ran concurrent with the THP-1 optimization protocol.  After 15 
minutes, the cells were washed with PBS and spun at 1800 rpm for 5 minutes, twice.  100 μL of 
Trypsin was added to each well to detach the cells from the flat-bottom plates, and the cells were 
transferred to a round-bottom plate.  The cells were washed a final time to remove the Trypsin 
and then resuspended in 2% PFA for flow analysis.  SYTOX Orange positive cell (% dead cells) 
data obtained from flow cytometry for A549 Trials 1 & 2 is displayed in Figure 6 and data from 
statistical analyses are displayed in Table 3. 
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3.0  RESULTS 
3.1 TOXICITY ASSAY USING U937 CELLS: TRIAL 1 
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Figure 1: Toxic Effects of AMPs on U937 Cells, Trial 1 
  
 
Following flow cytometry on the experimental samples and controls for U937 Trial 1, the data 
was stratified between cells positive and negative for SYTOX Orange, then expressed as 
percentages.  SYTOX Orange positive cells (% dead cells) data is shown.  Only 3% of the 
stained untreated controls were dead, denoted by a horizontal line on Figure 1.  Concentrations 
above 1 μM resulted in a substantial proportion of dead cells in all peptides, suggesting 
concentrations >= 20 μM are cytotoxic to U937 cells when compared to untreated controls.    
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3.2 TOXICITY ASSAY USING U937 CELLS: TRIALS 1 – 2 
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Figure 2: Toxic Effects of AMPs on U937 Cells, Trials 1 – 2 
 
The data from U937 Trial 2 reiterated the key finding from the data in U937 Trial 1.  All 
concentrations of peptide greater than 1 μM showed dramatically elevated percentages of overall 
cell death.  Interestingly, the 100 μM concentration of peptide D8 consistently returned fewer 
dead cells than any other D8 concentration examined, excluding 1 μM D8.  A possible 
justification for this outcome is addressed in the discussion section.  The untreated controls in 
both Trials 1 and 2 consistently maintained a low (3-4%) dead cell count, which reiterates the 
cytotoxicity of all three AMPs at higher concentrations.   
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3.3 TOXICITY ASSAY USING U937 CELLS:  TRIALS 3 – 4 
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Figure 3: Toxic Effects of AMPs on U937 Cells, Trials 3 – 4 
 
Mean values of (% dead cells) from U937 Trials 3 and 4 continued the trend of peptides >20 μM 
showing a marked increase in cell death, compared to all other concentrations of the same 
peptide under observation.  8 μM of any AMP was comparable in cytotoxicity to the other four 
reduced concentrations (1.6 μM, 0.32 μM, 0.064 μM, 0.012 μM).  This is an eightfold increase 
over the previously negligible percentage of overall cell death at 1.0 μM, yet nearly half the 
concentration of the 20 μM AMP concentration where significant overall cell death was present 
in previous trials.   Cell death in untreated controls increased from 3.5% (Trials 1 and 2) to an 
average of 6%, but this appeared to be consistent in all cultures in Trials 3 and 4. 
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3.4 TOXICITY ASSAY USING U937 CELLS: TRIALS 5 – 7 
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Figure 4: Toxic Effects of AMPs on U937 Cells, Trials 5 – 7 
 
Table 1: Dunnett’s Multiple Comparisons Test of Peptide vs Controls: U937 Cells 
Peptide Concentration (μM) 
Mean 
Diff. 95.00% CI of diff. 
Adjusted P 
Value 
A4S7 40 -82.6 -117.8 to -47.36 0.0001 
A4S7 20 -77.73 -113 to -42.5 0.0001 
A4S7 10 -37.47 -72.7 to -2.23 0.0327 
D8 40 -54.37 -89.6 to -19.13 0.0008 
WLBU2 40 -51.47 -86.7 to -16.23 0.0016 
WLBU2 20 -77.17 -112.4 to -41.93 0.0001 
WLBU2 10 -49.77 -85 to -14.53 0.0023 
 
 
U937 Trials 5 - 7 further reinforce the data obtained from earlier trials with data from additional 
peptide concentrations.  A two-way ANOVA with Dunnett’s multiple comparisons test was 
completed using GraphPad Prism.  The mean percentage of dead cells of each experimental 
AMP concentration was compared to the mean percentage of dead cells in untreated controls to 
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assess for significant differences (p value < 0.05), and all significant values are listed in Table 1.  
Peptides A4S7 and WLBU2 showed significant differences in percentage of dead cells when 
compared to controls for all concentrations >= 10 μM.  Peptide D8 was only significantly 
different (high percentage of dead cells) from the mean control value when the concentration was 
at its highest: 40 μM.  This suggests A4S7 and WLBU2 are more cytotoxic to U937 cells than 
D8 at lower concentrations.  As demonstrated in trials 3 and 4, there were still no significant 
differences in percentage of dead cells between controls and any peptide concentrations <=5 μM, 
suggesting peptides at this concentration are not killing U937 cells.  
3.5 TOXICITY ASSAY USING THP-1 CELLS: TRIALS 1 – 3 
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Figure 5: Toxic Effects of AMPs on THP-1 Cells, Trials 1 – 3 
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Table 2: Dunnett’s Multiple Comparisons Test of Peptide vs Controls: THP-1 Cells 
Peptide Concentration (μM) Mean Diff. 95.00% CI of diff. 
Adjusted P 
Value 
A4S7 40 -93.54 -114.7 to -72.35 0.0001 
A4S7 20 -93.11 -114.3 to -71.91 0.0001 
A4S7 10 -60.14 -81.33 to -38.95 0.0001 
D8 40 -29.81 -51 to -8.614 0.0025 
D8 20 -86.84 -108 to -65.65 0.0001 
D8 10 -73.97 -95.17 to -52.78 0.0001 
D8 5 -34.67 -55.87 to -13.48 0.0004 
WLBU2 40 -93.97 -115.2 to -72.78 0.0001 
WLBU2 20 -95.84 -117 to -74.65 0.0001 
WLBU2 10 -93.64 -114.8 to -72.45 0.0001 
     
 
 
Data from THP Trials 1 – 3 is provided above.  When exposed to any of the three peptides at 
concentrations >=20 μM, most THP-1 cells appear to be dead.  At only 10 μM of any peptide, at 
least 60% of THP-1 cells are dead, especially THP-1 cells exposed to WLBU2 (96% dead).   
Based on a two-way ANOVA with multiple comparisons, a statistically significant difference (p 
< 0.05) exists between the mean percentage of dead cells in untreated controls and any 
experimental peptide at 10 μM or higher concentration (Table 2).    At a peptide concentration of 
5 μM, THP-1 cells exposed to D8 were most sensitive with 37% dead cells, then WLBU2 at 
20%, and A4S7 at 9%.  At 5 μM, D8 was the only peptide with a significant difference from the 
control value (p = 0.0004).  These results for D8 are in sharp contrast to those obtained in the 
U937 trials, as D8 was comparably less cytotoxic at higher concentrations.  All THP-1 cells 
showed minimal cell death for any peptide at 2.5 μM or less and were not found to be 
statistically significant when compared to control values at those concentrations. 
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3.6 TOXICITY ASSAY USING A549 CELLS: TRIALS 1 – 2 
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Figure 6: Toxic Effects of AMPs on A549 Cells, Trials 1 – 2 
 
Table 3: Dunnett’s Multiple Comparisons Test of Peptide vs Controls: A549 Cells 
Peptide Concentration (μM) Mean Diff. 95.00% CI of diff. Adjusted P Value 
A4S7 40 -49.25 -73.11 to -25.39 0.0001 
A4S7 20 -37.1 -60.96 to -13.24 0.0012 
A4S7 10 -30.25 -54.11 to -6.395 0.0089 
WLBU2 40 -61.85 -85.71 to -37.99 0.0001 
WLBU2 20 -60.9 -84.76 to -37.04 0.0001 
WLBU2 10 -27.55 -51.41 to -3.695 0.0189 
 
 
Data from A549 Trials 1 and 2 is displayed above.  21.4% of untreated controls were dead 
following flow analysis, which was much higher than prior experiments, and is addressed in the 
discussion.  Despite this, significant differences between controls and peptide were observed.   
At concentrations as low as 10 μM, A4S7 and WLBU2 produced significant (p < 0.05) cell death 
when compared to untreated controls.  No concentrations of A4S7 or WLBU2 below 10 μM 
showed any meaningful differences from untreated controls in cell death.  This finding is 
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consistent across all three types of human-like monocyte that were used in the study.  No 
concentration of D8 was associated with significant differences from untreated controls. 
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4.0  DISCUSSION 
AMPs are widely used across the eukaryotic kingdom as a strategy to combat prokaryotic 
pathogens.  Despite the thousands of AMPs that have been discovered, little research has been 
done on the interaction between mycobacteria and these first responders of the innate immune 
system.  The disinclination of AMPs to interact with our cells and to preferentially destroy non-
eukaryotic cells may have profound implications as a means of treatment.  In this study, we 
attempted to identify the concentrations at which three specific AMPs become cytotoxic to both 
monocytes and epithelial cells during long (24-hour) exposures.  The outcomes of these 
concentrations can then be compared to parallel experiments with BCG and Mtb to identify a 
possible minimum inhibitory concentration that attacks the bacteria with minimal collateral 
damage to human cells. 
U937 Trial 1 (Figure 1) suggested that, for all three peptides, the ideal concentration for 
minimum cytotoxic impact was likely between 20 μM and 1 μM.  Interestingly, very high 
concentrations of D8 and WLBU2 produced unexpected amounts of cell death.  In both peptides, 
100 μM had a lower percentage of cell death than 20 μM of the same peptide.  It may be that 
extremely high concentrations of these peptides may not only perforate the cell membrane but 
also cause significant damage to DNA.  As STYOX Orange, a nucleic acid stain, would be 
incapable of binding to the damaged DNA, the result is an underrepresented percentage of cell 
death.  The experiment was repeated to verify the notion that high concentrations of peptide 
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damage DNA, thus leading to low cell death, and not that the initial results were simply a 
consequence of poor lab technique.  Mean values for U937 Trials 1 and 2 (Figure 2) suggested 
earlier assumptions were likely correct, as high concentrations of peptide returned low overall 
percentages of cell death in each of the three peptides once again. 
For U937 Trials 3 and 4, the intent was to capture cell death data in the 1 μM to 40 μM 
range that was previously unexamined in detail and determine if the cells were predictably 
insensitive to small concentrations of peptide. Therefore, a fivefold dilution series was 
introduced. Mean values from U937 Trials 3 and 4 (Figure 3) fail to demonstrate any major 
differences between concentrations of peptide < 8 μM and untreated controls.  This was not a 
surprising outcome as the cells were basically being incubated overnight in their preferred media 
at these low peptide concentrations.  The only unusual value was the low percentage of cell death 
at 40 μM of D8, however given the high percentage of cell death in U937 Trials 1 and 2 at the 
same concentration, the outcome was likely an outlier.  It became clear that the range at which 
cytotoxicity gradually decreases as concentrations decrease was going to be between 1 μM to 20 
μM. 
U937 Trials 5, 6 and 7 (Figure 4) utilize the concentrations that were reiterated 
throughout the rest of the assays.  After running the experiment in triplicate, A4S7 and WLBU2 
displayed a clear contrast between 5 μM and 10 μM where, as measured by percentage of cell 
death, the cytotoxic outcomes noticeably diverged despite the small range.  The percentage of 
cell death sharply dropped for D8 from noticeably cytotoxic to negligible as concentration 
decreased.  A multiple comparisons test was performed as the goal of the experiment to assess 
cytotoxicity of each concentration, individually, against an untreated control.  Dunnett’s test was 
used because this particular test is ideal for analyses that compare many experimental outcomes 
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against the same control samples.  Using an alpha of 0.05, Dunnett’s multiple comparisons test 
confirmed that A4S7 and WLBU2 both showed significant differences in cell death for all 
concentrations >= 10 μM when compared to untreated controls.  This could indicate that both 
peptides are unfavorable as treatment AMPs as 1) small changes in concentrations have dramatic 
outcomes in cytotoxicity and 2) small concentrations are necessary for negligible human cell 
cytotoxicity which might undermine effectiveness against bacteria.  Conversely, a minimum of 
40 μM of D8 was required to produce results significantly different than untreated controls, and 
(assuming there is a concentration at which D8 is effective against bacteria like Mtb) the gradual 
transition in cytotoxicity and low overall cytotoxic effects suggest D8 is a better, potential 
therapeutic candidate. 
THP-1 Trials 1, 2 and 3 (Figure 5) were undertaken to see if the results obtained in the 
U937 trials were only applicable to that particular cell line, or if other monocytes would show 
similar results.  Based on mean percentage of cell death, THP-1 cells appeared to be more 
sensitive to exposure to the various AMPs than their U937 counterparts.  (Table 2) In both A4S7 
and WLBU2, concentrations >= 10 μM were still necessary for a significant difference to emerge 
from untreated controls, but the p values were less uncertain when compared to the U937 trials.    
Interestingly, concentrations as low as 5 μM for D8 were sufficient to indicate a significant 
difference from untreated controls.  This is a sharp contrast from U937 trials and lends a degree 
of uncertainty to the likelihood of D8 as a viable intervention option if we assume that THP-1 
cells are a sufficient indicator of outcomes in actual human monocytes.  While D8’s cytotoxicity 
in this experiment may only be slightly higher than A4S7 and WLBU2, the inconsistency 
between cell lines is a cause for concern. 
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The administration of AMPs in the treatment of Mtb could possibly be best accomplished 
through inhalation, and not ingestion or intravenous administration.  This has a few clear 
advantages: 1) More targeted approach to the sites of infection, potentially increasing 
effectiveness 2) Less opportunity for unintended side effects as the peptides are not circulating 
through the body en masse before arriving at their destination, and 3) even if the peptides cannot 
penetrate granulomas and destroy latent Mtb, they might be capable of clearing extracytosolic 
bacteria and reduce transmission.  Therefore, A549 Trials 1 and 2 (Figure 6) were completed to 
observe the predicted effects of the experimental peptides on lung epithelia.  If the peptides are 
too toxic to be administered to lung cells, then the ability of the AMPs to degrade Mtb is largely 
irrelevant.   The adherent cell line required a greater degree of maintenance and manipulation 
than the cells in suspension, and this likely contributed to the elevated percentage of cell death in 
the untreated controls.  (Table 3) Consistent with the previous experiments in non-adherent cells, 
concentrations >= 10 μM in both A4S7 and WLBU2 demonstrated a significant difference in cell 
death when compared to untreated controls.  The consistency of A4S7 and WLBU2’s percentage 
of cell death across all experimental cell lines is reassuring for making predictions, however the 
cytotoxicity at lower concentrations continues to be a cause for concern.  No concentration of D8 
significantly differed from untreated controls at an alpha of 0.05.  This outcome further 
contributes to the inconsistency of D8’s cytotoxicity and complicates the possibility of the 
peptide as a possible treatment tool. 
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4.1 FUTURE DIRECTIONS 
The largest limitation of the study is the inability to do much with this information as the 
bacterial assays are still presently underway.  Each conclusion regarding the efficacy of 
individual peptides are best interpreted tentatively until additional replications are completed.  In 
the future, administration of these seven concentrations of peptides will be repeated on BCG and 
clinical isolates of Mtb.  The minimum inhibitory concentration can be compared to the 
cytotoxicity data obtained here to see if there exists a plausible intervention.  Additional factors 
like cytotoxicity over time will need to be introduced in the replications.  A disk diffusion 
protocol with BCG is presently ongoing to visually demonstrate the extent of each peptide’s 
ability to inhibit growth.  Lastly, we will want to repeat these experiments with BCG- and Mtb-
infected macrophages to determine whether AMPs have the ability to kill mycobacteria 
extracellularly and intracellularly. 
 Despite the dearth of data on bacteria, we have learned a few important things.   Both 
WLBU2 and A4S7 are likely cytotoxic to monocytes and epithelial cells at concentrations >=10 
μM for 24 hours of sustained exposure.  This result was consistent and significant across all 
repeated trials for both peptides.  D8 has no significant cytotoxicity to A549 cells when 
compared to untreated controls, limited cytotoxicity to U937 cells only at very high 
concentrations and pronounced cytotoxicity to THP-1 cells at any concentration above 5 μM.  
The inconsistency of D8 across cell types will likely pose a challenge to its use as a viable 
treatment. 
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